Oncotelic Presents PDAOAI Platform and HCC Four-Gene Signature
Oncotelic Therapeutics presented its PDAOAI platform and an exploratory four-gene mTOR-related signature linked to HCC survival at Drug Discovery 2026.
Oncotelic Therapeutics presented its PDAOAI platform and an exploratory four-gene mTOR-related signature linked to HCC survival at Drug Discovery 2026.